Q-omics provides the consensus-scored MS4A5 profile across patient tissues and cancer cell-line models. MS4A5 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MS4A5 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, MS4A5 RNA expression shows 6,456 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, KIRC, and STAD as cancer lineages where MS4A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MS4A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MS4A5 survival associations across molecular data types. MS4A5 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MS4A5 RNA expression–survival associations across cancer types. High MS4A5 expression shows unfavorable associations in CESC, LIHC, DLBC, ACC and PCPG, but favorable associations in ESCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify CESC as the clearest survival context for MS4A5 RNA expression.
This table summarizes MS4A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MS4A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MS4A5 shows lower tumor expression in KIRC and higher tumor expression in BLCA, BRCA, HNSC and LUSC. The KIRC box plot shows higher MS4A5 RNA expression in normal versus tumor tissue (log2 FC = −0.020, t-test p < 0.001).
This table shows molecular features associated with MS4A5 in patient tissues and cancer cell lines. In patient samples, MS4A5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MS4A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
